Merck Arcoxia Safety Board Allows Long-Term Trials To Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
The ongoing trials of etoricoxib are likely to continue through at least 2006. Merck is conducting the EDGE-2 and MEDAL studies to support resubmission of its NDA for the follow-on COX-2 inhibitor.